BP 1003
Alternative Names: BP-1003; Liposomal Stat-3Latest Information Update: 05 Sep 2024
Price :
$50 *
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Bio-Path Holdings
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action RNA interference; STAT3 transcription factor expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Breast cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 03 Sep 2024 Bio-Path Holdings expects to file an IND application for BP 1003 for Solid tumours
- 15 Apr 2024 Bio-Path Holdings has patent protection for P-ethoxy nucleic acids for STAT3 inhibition in Australia
- 21 Nov 2023 Preclinical development in Pancreatic-cancer is still ongoing in USA (IV, Infusion) (Bio-Path Holdings pipeline, November 2023)